| Name | Title | Contact Details |
|---|
Cutera was established in the San Francisco Bay Area (Brisbane) in 1998 by veteran laser and optical engineers. As the pioneer of Nd:YAG technology, CUTERA® is the trusted authority in Face + Body energy-based medical aesthetic technologies that practitioners around-the-world turn to for innovation, sophistication and performance. At Cutera, we`re always looking forward; developing new solutions, products and industry-leading services designed around the needs of medical aesthetic community—delivering better results, faster and safer than ever before. CUTERA`s premium portfolio of products include: xeo®, truSculpt® and excel V™. In 2014, CUTERA introduced two new exciting additions to their family of premium products: excel HR™ for high-speed, comfortable, hair removal and enlighten™, the industry`s first Picosecond + Nanosecond + 2 Wavelength High-Powered laser system. Today, our worldwide presence is represented in 40 countries, with direct operations in North America, France, Australia, Belgium, the Netherlands and Luxembourg.
GlucoTec is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IMTEC Corp (Main) US HQ is a Ardmore, OK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
ZLB Plasma Services is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.